FBIO FORTRESS BIOTECH INC revenue, earnings and financials

For the quarter ended June 30, 2026, FORTRESS BIOTECH INC reported revenue of $18.7M (up 14.0% from a year earlier), net income of −$468K and diluted EPS of −$0.08; over the last four quarters revenue was $68.5M and net income $142M; for the fiscal year ended December 2025 revenue was $63.3M, up 9.7% on the year before.

FBIO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $63.3M, gross profit n/a, operating income −$70.2M, net income $37.0M (margin 58.5%), EPS −$0.07
• Fiscal year ended Dec 2024: revenue $57.7M, gross profit n/a, operating income −$110M, net income $21.0M (margin 36.4%), EPS −$2.69
• Fiscal year ended Dec 2023: revenue $84.5M, gross profit n/a, operating income −$142M, net income $31.0M (margin 36.7%), EPS −$8.47
• Fiscal year ended Dec 2022: revenue $75.7M, gross profit n/a, operating income −$204M, net income −$86.6M (margin -114.3%), EPS −$15.97
• Fiscal year ended Dec 2021: revenue $68.8M, gross profit n/a, operating income −$189M, net income −$64.7M (margin -94.1%), EPS −$0.79

FBIO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $18.7M (up 14.0% year over year), net income −$468K, EPS −$0.08
• Quarter ended Mar 31, 2026: revenue $16.0M (up 22.1% year over year), net income $110M, EPS $2.82
• Quarter ended Dec 31, 2025 (from the annual report): revenue $16.1M (up 6.3% year over year), net income $26.2M, EPS −$0.15
• Quarter ended Sep 30, 2025: revenue $17.6M (up 20.5% year over year), net income $5.85M, EPS $0.11
• Quarter ended Jun 30, 2025: revenue $16.4M (up 10.2% year over year), net income $15.5M, EPS $0.45
• Quarter ended Mar 31, 2025: revenue $13.1M (up 0.8% year over year), net income −$10.6M, EPS −$0.48
• Quarter ended Dec 31, 2024 (from the annual report): revenue $15.1M (down 24.2% year over year), net income $60.2M, EPS −$0.16
• Quarter ended Sep 30, 2024: revenue $14.6M (down 57.9% year over year), net income −$12.9M, EPS −$0.76
• Quarter ended Jun 30, 2024: revenue $14.9M (down 14.3% year over year), net income −$10.9M, EPS −$0.73
• Quarter ended Mar 31, 2024: revenue $13.0M (up 4.8% year over year), net income −$15.4M, EPS −$1.04
• Quarter ended Dec 31, 2023 (from the annual report): revenue $19.9M (up 21.6% year over year), net income $82.4M, EPS −$3.67
• Quarter ended Sep 30, 2023: revenue $34.8M (up 110.3% year over year), net income −$5.05M, EPS −$0.94
• Quarter ended Jun 30, 2023: revenue $17.4M (down 7.9% year over year), net income −$24.8M, EPS −$3.65
• Quarter ended Mar 31, 2023: revenue $12.4M (down 48.1% year over year), net income −$21.5M, EPS −$0.21
• Quarter ended Dec 31, 2022 (from the annual report): revenue $16.4M (down 10.2% year over year), net income −$26.9M, EPS −$11.42
• Quarter ended Sep 30, 2022: revenue $16.5M (down 21.6% year over year), net income −$22.5M, EPS −$4.11
• Quarter ended Jun 30, 2022: revenue $18.9M (up 5.8% year over year), net income −$21.4M, EPS −$0.26
• Quarter ended Mar 31, 2022: revenue $23.9M (up 106.5% year over year), net income −$15.8M, EPS −$0.18
• Quarter ended Dec 31, 2021 (from the annual report): revenue $18.3M, net income −$31.6M, EPS −$0.38
• Quarter ended Sep 30, 2021: revenue $21.1M, net income −$20.8M, EPS −$0.26

FBIO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$65.8M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$80.2M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$128M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$179M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$117M, share buybacks n/a

FBIO balance sheet

• Jun 30, 2026: cash $197M, total assets $317M, total liabilities $111M, shareholders' equity $164M
• Mar 31, 2026: cash $256M, total assets $357M, total liabilities $155M, shareholders' equity $162M
• Dec 31, 2025: cash $79.4M, total assets $186M, total liabilities $123M, shareholders' equity $49.9M
• Sep 30, 2025: cash $86.2M, total assets $181M, total liabilities $116M, shareholders' equity $55.9M
• Jun 30, 2025: cash $74.4M, total assets $160M, total liabilities $123M, shareholders' equity $43.9M
• Mar 31, 2025: cash $91.3M, total assets $178M, total liabilities $146M, shareholders' equity $22.3M
• Dec 31, 2024: cash $57.3M, total assets $144M, total liabilities $146M, shareholders' equity $22.7M
• Sep 30, 2024: cash $58.9M, total assets $127M, total liabilities $140M, shareholders' equity $21.2M

What is FBIO's revenue?

FORTRESS BIOTECH INC reported $68.5M of revenue over its last four quarters, through June 30, 2026.

Is FBIO profitable?

Yes. FORTRESS BIOTECH INC earned $142M over the last four quarters.

What is FBIO's EPS?

Diluted earnings per share over the last four quarters were $2.70; −$0.08 in the latest quarter.

FBIO ownership and insider trades · All stocks